Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms SURMOUNT-1
- Sponsors Eli Lilly and Company
Most Recent Events
- 29 May 2025 According to Eli Lilly and Company media release, company announced that data from this study will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago.
- 01 May 2025 Results (n=255) from substudy of this trial performed for participants with obesity or overweight from the SURMOUNT-1 trial were published in the Diabetes, Obesity and Metabolism.
- 01 Feb 2025 Results assessing changes in patient-reported outcomes (PROs) assessing physical function, psychosocial well-being, and overall health aspects of participants' health-related quality of life published in the Diabetes, Obesity and Metabolism